Eli Lilly and Novo Nordisk are two dividend stocks that are worth considering for investors looking to boost their portfolio returns. Both pharmaceutical giants have demonstrated strong performance and have promising growth prospects in the coming years.
Eli Lilly, despite its premium valuation, has been on an impressive streak with its shares soaring by 269% in the past 36 months. The company’s groundbreaking treatments for conditions like Alzheimer’s disease and obesity have contributed to its stock reaching new heights. Additionally, Eli Lilly has a robust product portfolio and clinical pipeline, ensuring long-term sustainability. While its dividend yield is modest at 0.82%, its safety and strong growth potential make it an attractive investment option.
On the other hand, Novo Nordisk is a global leader in diabetes and obesity management. With a market value of almost $408 billion, the Danish company has consistently grown its revenues and profits. Its exposure to the lucrative weight loss market has driven its shares to return nearly 260% in the past three years. Although Novo Nordisk’s dividend yield is not high, its low payout ratio of 41.5% and expected double-digit revenue growth indicate a sustainable dividend program in the long run.
In conclusion, both Eli Lilly and Novo Nordisk present compelling investment opportunities due to their strong performance, promising growth prospects, and sustainable dividend programs. While Eli Lilly may have a premium valuation, its innovative treatments and solid pipeline justify its price. Meanwhile, Novo Nordisk’s leadership in the diabetes and weight loss market positions it for continued success. By considering these dividend stocks, investors have the potential to benefit from both capital appreciation and compounding dividends over time.